{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:46:39Z","timestamp":1791229599282,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40263-022-00960-y","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T01:02:24Z","timestamp":1670979744000},"page":"143-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Estimating Risk of Antidepressant Withdrawal from a Review of Published Data"],"prefix":"10.1007","volume":"37","author":[{"given":"Mark Abie","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Framer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Hengartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-1710","authenticated-orcid":false,"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"960_CR1","unstructured":"NHS Business Services Authority. Medicines used in mental health England 2015\/16 to 2019\/20. 2020. Available from: https:\/\/nhsbsa-opendata.s3-eu-west-2.amazonaws.com\/mh-annual-narrative-final.html. Accessed 4 May 2021."},{"key":"960_CR2","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.3399\/bjgp12X658304","volume":"62","author":"CF Johnson","year":"2012","unstructured":"Johnson CF, Macdonald HJ, Atkinson P, Buchanan AI, Downes N, Dougall N. Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br J Gen Pract. 2012;62:e773\u20139.","journal-title":"Br J Gen Pract"},{"key":"960_CR3","unstructured":"Public Health England. Dependence and withdrawal associated with some prescribed medicines: an evidence review. 2019. Available from: https:\/\/www.gov.uk\/government\/publications\/prescribed-medicines-review-report. Accessed 25 May 2021."},{"key":"960_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0269881119845799","volume":"33","author":"S Jauhar","year":"2019","unstructured":"Jauhar S, Hayes J, Goodwin GM, Baldwin DS, Cowen PJ, Nutt DJ. Antidepressants, withdrawal, and addiction; where are we now? J Psychopharmacol. 2019;33:655\u20139.","journal-title":"J Psychopharmacol"},{"key":"960_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.addbeh.2018.08.027","volume":"97","author":"J Davies","year":"2019","unstructured":"Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav. 2019;97:111\u201321.","journal-title":"Addict Behav"},{"key":"960_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.addbeh.2019.02.007","volume":"97","author":"MP Hengartner","year":"2019","unstructured":"Hengartner MP. Commentary on Jauhar and Hayes. Addict Behav. 2019;97:131.","journal-title":"Addict Behav"},{"key":"960_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.addbeh.2019.01.026","volume":"97","author":"J Davies","year":"2019","unstructured":"Davies J, Read J. Authors\u2019 response to a critique by Jauhar and Hayes of \u201cA systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guideline evidence-based?\u201d Addict Behav. 2019;97:127\u201330.","journal-title":"Addict Behav"},{"key":"960_CR8","doi-asserted-by":"publisher","first-page":"204512532096718","DOI":"10.1177\/2045125320967183","volume":"10","author":"A Guy","year":"2020","unstructured":"Guy A, Brown M, Lewis S, Horowitz MA. The \u201cPatient Voice\u201d\u2014patients who experience antidepressant withdrawal symptoms are often dismissed, or mis-diagnosed with relapse, or onset of a new medical condition. Ther Adv Psychopharmacol. 2020;10:204512532096718.","journal-title":"Ther Adv Psychopharmacol."},{"key":"960_CR9","doi-asserted-by":"publisher","first-page":"204512532092169","DOI":"10.1177\/2045125320921694","volume":"10","author":"MP Hengartner","year":"2020","unstructured":"Hengartner MP. How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Ther Adv Psychopharmacol. 2020;10:2045125320921694.","journal-title":"Ther Adv Psychopharmacol."},{"key":"960_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1192\/apt.bp.105.001966","volume":"13","author":"PM Haddad","year":"2007","unstructured":"Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat. 2007;13:447\u201357.","journal-title":"Adv Psychiatr Treat"},{"key":"960_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.4088\/JCP.08m04943","volume":"70","author":"RJ Valuck","year":"2009","unstructured":"Valuck RJ, Orton HD, Libby AM. Antidepressant discontinuation and risk of suicide attempt. J Clin Psychiatry. 2009;70:1069\u201377.","journal-title":"J Clin Psychiatry"},{"key":"960_CR12","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0140-6736(05)72262-5","volume":"355","author":"A Young","year":"2000","unstructured":"Young A, Haddad P. Discontinuation symptoms and psychotropic drugs. Lancet. 2000;355:1184\u20135.","journal-title":"Lancet"},{"key":"960_CR13","doi-asserted-by":"publisher","first-page":"204512532098057","DOI":"10.1177\/2045125320980573","volume":"10","author":"MP Hengartner","year":"2020","unstructured":"Hengartner MP, Schulthess L, Sorensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Ther Adv Psychopharmacol. 2020;10:2045125320980573.","journal-title":"Ther Adv Psychopharmacol."},{"key":"960_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.addbeh.2019.01.025","volume":"97","author":"S Jauhar","year":"2019","unstructured":"Jauhar S, Hayes J. The war on antidepressants: what we can, and can\u2019t conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read. Addict Behav. 2019;97:122\u20135.","journal-title":"Addict Behav"},{"key":"960_CR15","first-page":"355","volume":"116","author":"J Henssler","year":"2019","unstructured":"Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant withdrawal and rebound phenomena. Dtsch Arztebl Int. 2019;116:355\u201361.","journal-title":"Dtsch Arztebl Int"},{"key":"960_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fphar.2013.00045","volume":"4","author":"T Renoir","year":"2013","unstructured":"Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol. 2013;4:45.","journal-title":"Front Pharmacol"},{"key":"960_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1360-0443.2010.03144.x","volume":"106","author":"C O\u2019Brien","year":"2011","unstructured":"O\u2019Brien C. Addiction and dependence in DSM-V. Addiction. 2011;106:866\u20137.","journal-title":"Addiction"},{"key":"960_CR18","first-page":"28","volume":"100","author":"American Academy of Pain Medicine, the American Pain Society and the American Society of Addition Medicine","year":"2001","unstructured":"American Academy of Pain Medicine, the American Pain Society and the American Society of Addition Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ. 2001;100:28\u20139.","journal-title":"WMJ"},{"key":"960_CR19","unstructured":"National Institute on Drug Abuse. Is there a difference between physical dependence and addiction?. National Institute on Drug Abuse. Available from: https:\/\/nida.nih.gov\/publications\/principles-drug-addiction-treatment-research-based-guide-third-edition\/frequently-asked-questions\/there-difference-between-physical-dependence-addiction. Accessed 31 May 2022."},{"key":"960_CR20","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"LL Brunton","year":"2011","unstructured":"Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman\u2019s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Education; 2011.","edition":"12"},{"key":"960_CR21","doi-asserted-by":"publisher","first-page":"fcz025","DOI":"10.1093\/braincomms\/fcz025","volume":"1","author":"A Lerner","year":"2019","unstructured":"Lerner A, Klein M. Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain Commun. 2019;1:fcz025.","journal-title":"Brain Commun."},{"key":"960_CR22","first-page":"9","volume":"48","author":"RH Howland","year":"2010","unstructured":"Howland RH. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv. 2010;48:9\u201312.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"960_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jad.2006.04.026","volume":"95","author":"D Taylor","year":"2006","unstructured":"Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms: telephone calls to a national medication helpline. J Affect Disord. 2006;95:129\u201333.","journal-title":"J Affect Disord"},{"issue":"12","key":"960_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.mpmed.2016.09.007","volume":"44","author":"S Turton","year":"2016","unstructured":"Turton S, Lingford-Hughes A. Neurobiology and principles of addiction and tolerance. Medicine. 2016;44(12):693\u20136.","journal-title":"Medicine."},{"key":"960_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1176\/ajp.153.2.151","volume":"153","author":"SE Hyman","year":"1996","unstructured":"Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 1996;153:151\u201362.","journal-title":"Am J Psychiatry"},{"key":"960_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/026988119901300321","volume":"13","author":"P Haddad","year":"1999","unstructured":"Haddad P. Do antidepressants have any potential to cause addiction? J Psychopharmacol. 1999;13:300\u20137.","journal-title":"J Psychopharmacol"},{"key":"960_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1124\/jpet.111.183285","volume":"339","author":"MM Reidenberg","year":"2011","unstructured":"Reidenberg MM. Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther. 2011;339:324\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"960_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00023210-199912030-00001","volume":"12","author":"JS Olver","year":"1999","unstructured":"Olver JS, Burrows GD, Norman TR. Discontinuation syndromes with selective serotonin reuptake inhibitors. CNS Drugs. 1999;12:171\u20137.","journal-title":"CNS Drugs"},{"key":"960_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1176\/appi.ajp.158.1.78","volume":"158","author":"JH Meyer","year":"2001","unstructured":"Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, et al. The effect of paroxetine on 5-HT2Areceptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry. 2001;158:78\u201385.","journal-title":"Am J Psychiatry"},{"key":"960_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/mp.2013.147","volume":"19","author":"ME Haahr","year":"2014","unstructured":"Haahr ME, Fisher PM, Jensen CG, Frokjaer VG, McMahon B, Madsen K, et al. Central 5-HT4receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study. Mol Psychiatry. 2014;19:427\u201332.","journal-title":"Mol Psychiatry"},{"key":"960_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.biopsych.2012.11.012","volume":"74","author":"NA Gray","year":"2013","unstructured":"Gray NA, Milak MS, DeLorenzo C, Ogden RT, Huang Y-Y, Mann JJ, et al. Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry. 2013;74:26\u201331.","journal-title":"Biol Psychiatry"},{"key":"960_CR32","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/sj.mp.4001401","volume":"9","author":"Z Bhagwagar","year":"2004","unstructured":"Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry. 2004;9:386\u201392.","journal-title":"Mol Psychiatry"},{"key":"960_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JCP.0b013e3181c8ae80","volume":"30","author":"Y Murata","year":"2010","unstructured":"Murata Y, Kobayashi D, Imuta N, Haraguchi K, Ieiri I, Nishimura R, et al. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010;30:11\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"960_CR34","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.nut.2005.04.002","volume":"21","author":"R Quinn","year":"2005","unstructured":"Quinn R. Comparing rat\u2019s to human\u2019s age: how old is my rat in people years? Nutrition. 2005;21:775\u20137.","journal-title":"Nutrition"},{"key":"960_CR35","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.neuint.2010.10.001","volume":"57","author":"FJ Bosker","year":"2010","unstructured":"Bosker FJ, Tanke MAC, Jongsma ME, Cremers TIFH, Jagtman E, Pietersen CY, et al. Biochemical and behavioral effects of long-term citalopram administration and discontinuation in rats: role of serotonin synthesis. Neurochem Int. 2010;57:948\u201357.","journal-title":"Neurochem Int"},{"key":"960_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejphar.2010.08.026","volume":"647","author":"Y Kitaichi","year":"2010","unstructured":"Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, et al. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol. 2010;647:90\u20136.","journal-title":"Eur J Pharmacol"},{"key":"960_CR37","first-page":"561","volume":"288","author":"DK Raap","year":"1999","unstructured":"Raap DK, Garcia F, Muma NA, Wolf WA, Battaglia G, van de Kar LD. Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(dipropylamino)tetralin in the absence of changes in Gi\/o\/z proteins. J Pharmacol Exp Ther. 1999;288:561\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 4","key":"960_CR38","first-page":"8","volume":"67","author":"P Blier","year":"2006","unstructured":"Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry. 2006;67(Suppl. 4):8\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 7","key":"960_CR39","first-page":"5","volume":"58","author":"AF Schatzberg","year":"1997","unstructured":"Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus Panel. J Clin Psychiatry. 1997;58(Suppl. 7):5\u201310.","journal-title":"J Clin Psychiatry"},{"key":"960_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.","journal-title":"Res Integr Peer Rev."},{"key":"960_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","volume":"44","author":"JF Rosenbaum","year":"1998","unstructured":"Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77\u201387.","journal-title":"Biol Psychiatry"},{"key":"960_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","volume":"160","author":"R Levinson-Castiel","year":"2006","unstructured":"Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173\u20136.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"960_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00004850-200015060-00001","volume":"15","author":"I Hindmarch","year":"2000","unstructured":"Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol. 2000;15:305\u201318.","journal-title":"Int Clin Psychopharmacol"},{"key":"960_CR44","first-page":"297","volume":"28","author":"MA Horowitz","year":"2022","unstructured":"Horowitz MA, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. B J Psych Adv. 2022;28:297\u2013311.","journal-title":"B J Psych Adv."},{"key":"960_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00004714-199806000-00003","volume":"18","author":"J Zajecka","year":"1998","unstructured":"Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, et al. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol. 1998;18:193\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"960_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/026988110101500210","volume":"15","author":"P Haddad","year":"2001","unstructured":"Haddad P, Devarajan S, Dursun S. Antidepressant discontinuation (withdrawal) symptoms presenting as \u201cstroke.\u201d J Psychopharmacol. 2001;15:139\u201341.","journal-title":"J Psychopharmacol"},{"key":"960_CR47","volume-title":"Report of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitors antidepressants","author":"I Weller","year":"2005","unstructured":"Weller I, Ashby D, Chambers M, Chick J, Drummond C, Ebmeier K, et al. Report of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitors antidepressants. London: MHRA; 2005."},{"key":"960_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1192\/bjp.169.3.384a","volume":"169","author":"L Pacheco","year":"1996","unstructured":"Pacheco L, Malo P, Aragues E, Etxebeste M. More cases of paroxetine withdrawal syndrome. Br J Psychiatry. 1996;169:384.","journal-title":"Br J Psychiatry"},{"issue":"Suppl. 7","key":"960_CR49","first-page":"37","volume":"58","author":"JF Rosenbaum","year":"1997","unstructured":"Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997;58(Suppl. 7):37\u201340.","journal-title":"J Clin Psychiatry"},{"key":"960_CR50","unstructured":"Davies J, Regina P, Montagu L. Antidepressant withdrawal: a survey of patients\u2019 experience by the All-Party Parliamentary Group for Prescribed Drug Dependence. All-Party Parliamentary Group for Prescribed Drug Dependence; 2018. Available from: http:\/\/prescribeddrug.org\/wp-content\/uploads\/2018\/10\/APPG-PDD-Survey-of-antidepressant-withdrawal-experiences.pdf. Accessed 7 Oct 2022."},{"key":"960_CR51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2174\/1574886313666180605095130","volume":"13","author":"J Read","year":"2018","unstructured":"Read J, Williams J. Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality, and withdrawal effects. Curr Drug Saf. 2018;13:176\u201386.","journal-title":"Curr Drug Saf"},{"key":"960_CR52","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.4088\/JCP.v66n1015","volume":"66","author":"A Sir","year":"2005","unstructured":"Sir A, D\u2019Souza RF, Uguz S, George T, Vahip S, Hopwood M, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005;66:1312\u201320.","journal-title":"J Clin Psychiatry"},{"key":"960_CR53","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1046\/j.1365-2125.1996.00498.x","volume":"42","author":"JS Price","year":"1996","unstructured":"Price JS, Waller PC, Wood SM, Mackay AVP. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996;42:757\u201363.","journal-title":"Br J Clin Pharmacol"},{"key":"960_CR54","first-page":"e69","volume":"13","author":"NH Bhanji","year":"2006","unstructured":"Bhanji NH, Chouinard G, Kolivakis T, Margolese HC. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol. 2006;13:e69-74.","journal-title":"Can J Clin Pharmacol"},{"key":"960_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2238","volume":"365","author":"J Davies","year":"2019","unstructured":"Davies J, Read J, Hengartner MP, Cosci F, Fava G, Chouinard G, et al. Clinical guidelines on antidepressant withdrawal urgently need updating. BMJ. 2019;365: l2238.","journal-title":"BMJ"},{"key":"960_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.psychres.2014.01.042","volume":"216","author":"J Read","year":"2014","unstructured":"Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res. 2014;216:67\u201373.","journal-title":"Psychiatry Res"},{"key":"960_CR57","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/inm.12488","volume":"27","author":"J Read","year":"2018","unstructured":"Read J, Cartwright C, Gibson K. How many of 1829 antidepressant users report withdrawal effects or addiction? Int J Ment Health Nurs. 2018;27:1805\u201315.","journal-title":"Int J Ment Health Nurs"},{"key":"960_CR58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1461145705006358","volume":"10","author":"DS Baldwin","year":"2007","unstructured":"Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007;10:73\u201384.","journal-title":"Int J Neuropsychopharmacol"},{"key":"960_CR59","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","volume":"6","author":"MA Horowitz","year":"2019","unstructured":"Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:538\u201346.","journal-title":"Lancet Psychiatry"},{"key":"960_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.12793\/tcp.2018.26.2.56","volume":"26","author":"N Holford","year":"2018","unstructured":"Holford N. Pharmacodynamic principles and the time course of delayed and cumulative drug effects. Transl Clin Pharmacol. 2018;26:56.","journal-title":"Transl Clin Pharmacol."},{"key":"960_CR61","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","volume":"161","author":"JH Meyer","year":"2004","unstructured":"Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826\u201335.","journal-title":"Am J Psychiatry"},{"key":"960_CR62","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","volume":"6","author":"TA Furukawa","year":"2019","unstructured":"Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6:601\u20139.","journal-title":"Lancet Psychiatry"},{"key":"960_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1017\/S1461145705006413","volume":"10","author":"G Debonnel","year":"2007","unstructured":"Debonnel G, Saint-Andr\u00e9 \u00c9, H\u00e9bert C, De Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007;10:51\u201361.","journal-title":"Int J Neuropsychopharmacol"},{"key":"960_CR64","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/npp.2008.47","volume":"33","author":"MJ Owens","year":"2008","unstructured":"Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008;33:3201\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"960_CR65","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S2215-0366(19)30219-6","volume":"6","author":"MA Horowitz","year":"2019","unstructured":"Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms: authors\u2019 reply. Lancet Psychiatry. 2019;6:562\u20133.","journal-title":"Lancet Psychiatry"},{"key":"960_CR66","doi-asserted-by":"publisher","first-page":"204512532093791","DOI":"10.1177\/2045125320937910","volume":"10","author":"J Moncrieff","year":"2020","unstructured":"Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. Ther Adv Psychopharmacol. 2020;10:2045125320937910.","journal-title":"Ther Adv Psychopharmacol."},{"key":"960_CR67","first-page":"125","volume":"78","author":"MA Horowitz","year":"2021","unstructured":"Horowitz MA, Murray RM, Taylor D. Tapering antipsychotic treatment. JAMA. Psychiatry. 2021;78:125\u20136.","journal-title":"Psychiatry"},{"key":"960_CR68","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1192\/bjp.176.4.363","volume":"176","author":"D Michelson","year":"2000","unstructured":"Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363\u20138.","journal-title":"Br J Psychiatry"},{"key":"960_CR69","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000370338","volume":"84","author":"GA Fava","year":"2015","unstructured":"Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84:72\u201381.","journal-title":"Psychother Psychosom"},{"issue":"Suppl. 1","key":"960_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","volume":"32","author":"SH Preskorn","year":"1997","unstructured":"Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32(Suppl. 1):1\u201321.","journal-title":"Clin Pharmacokinet"},{"key":"960_CR71","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.56427","volume":"9","author":"JA Coleman","year":"2020","unstructured":"Coleman JA, Navratna V, Antermite D, et al. Chemical and structural investigation of the paroxetine-human serotonin transporter complex. Elife. 2020;9:e56427.","journal-title":"Elife."},{"key":"960_CR72","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/01.yic.0000137184.64610.c8","volume":"19","author":"SA Montgomery","year":"2004","unstructured":"Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19:271\u201380.","journal-title":"Int Clin Psychopharmacol"},{"key":"960_CR73","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jad.2021.10.041","volume":"297","author":"J-B Quilichini","year":"2021","unstructured":"Quilichini J-B, Revet A, Garcia P, Bouqui\u00e9 R, Hamard J, Yrondi A, et al. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: a real-world study using the WHO pharmacovigilance database. J Affect Disord. 2021;297:189\u201393.","journal-title":"J Affect Disord"},{"key":"960_CR74","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0269881116628440","volume":"30","author":"DS Baldwin","year":"2016","unstructured":"Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30:242\u201352.","journal-title":"J Psychopharmacol"},{"key":"960_CR75","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1517\/14740338.2011.582037","volume":"10","author":"I Bitter","year":"2011","unstructured":"Bitter I, Filipovits D, Czobor P. Adverse reactions to duloxetine in depression. Expert Opin Drug Saf. 2011;10:839\u201350.","journal-title":"Expert Opin Drug Saf"},{"key":"960_CR76","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S2215-0366(19)30182-8","volume":"6","author":"HG Ruhe","year":"2019","unstructured":"Ruhe HG, Horikx A, van Avendonk MJP, Groeneweg BF, Woutersen-Koch H. Discontinuation of Antidepressants Taskforce. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:561\u20132.","journal-title":"Lancet Psychiatry"},{"key":"960_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.euroneuro.2021.10.001","volume":"55","author":"MA Horowitz","year":"2021","unstructured":"Horowitz MA, Taylor D. How to reduce and stop psychiatric medication. Eur Neuropsychopharmacol. 2021;55:4\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"key":"960_CR78","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1192\/bjp.167.3.374","volume":"167","author":"S Oehrberg","year":"1995","unstructured":"Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995;167:36\u201342.","journal-title":"Br J Psychiatry"},{"key":"960_CR79","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.4088\/JCP.v66n1009","volume":"66","author":"SA Montgomery","year":"2005","unstructured":"Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger J-P. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005;66:1270\u20138.","journal-title":"J Clin Psychiatry"},{"key":"960_CR80","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","volume":"189","author":"DS Baldwin","year":"2006","unstructured":"Baldwin DS, Huusom AKT, Maehlum E. Escitalopram and paroxetine compared to placebo in the treatment of generalised anxiety disorder (GAD). Br J Psychiatry. 2006;189:264\u201372.","journal-title":"Br J Psychiatry"},{"key":"960_CR81","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/da.20014","volume":"19","author":"M Lader","year":"2004","unstructured":"Lader M, Stender K, B\u00fcrger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004;19:241\u20138.","journal-title":"Depress Anxiety"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00960-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00960-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00960-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T12:18:21Z","timestamp":1676290701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00960-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["960"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00960-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"20 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper was not supported by any funding. Mark Abie Horowitz is supported by a Clinical Research Fellowship through the North East London NHS Foundation Trust. This funding source had no role in the writing of the manuscript or the decision to submit it for publication. MAH is an honorary Clinical Research Fellow at UCL. The Psychiatry Research Trust funded the open access publication of this article. This funder was not involved in the planning or writing of the manuscript, or decision to submit for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anders S\u00f8rensen has no conflicts of interest. Mark Abie Horowitz declares that he is a co-founder of Outro Health, a company aiming to help people safely stop unnecessary antidepressants in Canada and North America. Adele Framer declares she is a co-founder of Outro Health. Michael P. Hengartner reports royalties from Palgrave Macmillan, London, UK for his book published in December, 2021, called \u201cEvidence-biased Antidepressant Prescription.\u201d David Taylor reports grants and personal fees from Janssen, Sunovion, Recordati and Mylan, and personal fees from Accord, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data in this study are available in the public domain.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MAH conceived the idea of the manuscript, conducted the searches and wrote the first draft. MPH performed the data analysis and contributed substantially to the manuscript. AF further developed the concepts of the paper and substantially contributed to the final form of the manuscript. AS and DT revised and contributed substantially to the final form of the manuscript. DT supervised the project. All authors have read and approve the final submitted manuscript and all agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}